Citations

Clear

367 citation(s) found for "Benson, Al".

Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal Gammopathies
Katzmann, Jerry A., Snyder, Melissa R, Rajkumar, S. Vincent , Kyle, Robert A. , Therneau, Terry M. , Benson, Joanne T., Dispenzieri, Angela , Snyder, Melissa R, Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Clinical Chemistry | October 7, 2011 | Volume: 57 | Issue: 12 | Pages: 1687-1692

10.1373/clinchem.2011.171314 | PMID 21980167 Get It

BACKGROUND We analyzed serial data in patients with clinically stable monoclonal gammopathy to determine the total variation of serum M-spikes [measured with serum protein electrophoresis (SPEP)], urine M-spikes [measured with urine protein electrophoresis (UPEP)], and monoclonal serum free light chain (FLC) concentrations measured with immunoassay. METHODS Patients to be studied were identified by (a) no treatment during the study interval, (b) no change in diagnosis and <5 g/L change in serum M-spike over the course of observation; (c) performance of all 3 tests (SPEP, UPEP, FLC immunoassay) in at least 3 serial samples that were obtained 9 months to 5 years apart; (d) serum M-spike ≥10 g/L, urine M-spike ≥200 mg/24 h, or clonal FLC ≥100 mg/L. The total CV was calculated for each method. RESULTS Among the cohort of 158 patients, 90 had measurable serum M-spikes, 25 had urine M-spikes, and 52 had measurable serum FLC abnormalities. The CVs were calculated for serial SPEP M-spikes (8.1%), UPEP M-spikes (35.8%), and serum FLC concentrations (28.4%). Combining these CVs and the interassay analytical CVs, we calculated the biological CV for the serum M-spike (7.8%), urine M-spike (35.5%), and serum FLC concentration (27.8%). CONCLUSIONS The variations in urine M-spike and serum FLC measurements during patient monitoring are similar and are larger than those for serum M-spikes. In addition, in this group of stable patients, a measurable serum FLC concentration was available twice as often as a measurable urine M-spike.
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
Feng, Yang , Cárdenes, Higinia R. , Brell, Joanna M., Cella, David , Flynn, Patrick J. , Ramanathan, Ramesh K., Crane, Christopher H. , Benson, Al B. , Loehrer, Patrick J. , Wagner, Lynne I. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | October 4, 2011 | Volume: 29 | Issue: 31 | Pages: 4105-4112

10.1200/jco.2011.34.8904 | PMID 21969502 Get It

Purpose The purpose of this trial was to evaluate the role of radiation therapy with concurrent gemcitabine (GEM) compared with GEM alone in patients with localized unresectable pancreatic cancer. Patients and Methods Patients with localized unresectable adenocarcinoma of the pancreas were randomly assigned to receive GEM alone (at 1,000 mg/m 2 /wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks) or GEM (600 mg/m 2 /wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m 2 for 3 of 4 weeks) plus radiotherapy (starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy). Measurement of quality of life using the Functional Assessment of Cancer Therapy–Hepatobiliary questionnaire was also performed. Results Of 74 patients entered on trial and randomly assigned to receive GEM alone (arm A; n = 37) or GEM plus radiation (arm B; n = 34), patients in arm B had greater incidence of grades 4 and 5 toxicities (41% v 9%), but grades 3 and 4 toxicities combined were similar (77% in A v 79% in B). No statistical differences were seen in quality of life measurements at 6, 15 to 16, and 36 weeks. The primary end point was survival, which was 9.2 months (95% CI, 7.9 to 11.4 months) and 11.1 months (95% CI, 7.6 to 15.5 months) for arms A and B, respectively (one-sided P = .017 by stratified log-rank test). Conclusion This trial demonstrates improved overall survival with the addition of radiation therapy to GEM in patients with localized unresectable pancreatic cancer, with acceptable toxicity.
Relative Quantification: Characterization of Bias, Variability and Fold Changes in Mass Spectrometry Data from iTRAQ-Labeled Peptides
Therneau, Terry M. , Heppelmann, Carrie J. , Higgins, LeeAnn, Benson, Linda M., Zenka, Roman M. , Jagtap, Pratik , Nelsestuen, Gary L., Bergen, H. Robert, Oberg, Ann L. , Mahoney, Douglas W. , Jagtap, Pratik D

Mayo Clinic

Journal of Proteome Research | July 14, 2011 | Volume: 10 | Issue: 9 | Pages: 4325-4333

10.1021/pr2001308 | PMID 21755926 Get It

II. Stroke Rehabilitation
Peszczynski, M, Benson, D. Frank , Collins, Joyce M., Darley, Frederic L., Greenhouse, Arnold H., Katzen, Faye P., Lake, Lorraine F., Rothberg, June S., Waggoner, Raymond, Diller, Leonard

Mayo Clinic

Stroke | June 17, 2011 | Volume: 3 | Issue: 3 | Pages: 375-407

10.1161/01.str.3.3.375 Get It

Rehabilitation offers means by which persons disabled after a stroke can be returned to patterns of daily living as close to normal as possible. Often simple and readily available restorative techniques suffice, but sophisticated methods and facilities may be needed in many cases. Certain complex problems require specialized attention by persons with detailed knowledge and specific training. Among these are rehabilitation of language and the management of incontinence, sensory loss, pain, spasticity, and psychosocial problems. High-quality rehabilitation is best delivered by a closely cooperating team, including the family physician, medical specialists, nurses, allied health professionals (physical therapist, occupational therapist, social worker, dietitian, rehabilitation counselor, speech therapist, psychologist), the patient's family, and also the patient. To accomplish these ends, hospitals, rehabilitation centers, extended care facilities, and nursing homes should give specific attention to the special needs of stroke patients. Careful discharge planning and follow-up are necessary in all cases. The home environment and the family attitudes may require considerable revision to meet the patient's individual needs. The family physician can offer many rehabilitation services in his office, and additional education in medical school and on a postgraduate level will belp him to reach his full potential in aiding both the acutely ill and the chronically disabled stroke patient.
Simultaneous Phenotyping and Quantification of α-1-Antitrypsin by Liquid Chromatography–Tandem Mass Spectrometry
Snyder, Melissa R, Zhu, Yi , Tostrud, Linda J., Benson, Linda M., Katzmann, Jerry A., Bergen, H. Robert, Chen, Yuhong , Snyder, Melissa R, Zhu, Yi

Mayo Clinic

Clinical Chemistry | June 3, 2011 | Volume: 57 | Issue: 8 | Pages: 1161-1168

10.1373/clinchem.2011.163006 | PMID 21636698 Get It

BACKGROUNDα-1-Antitrypsin (A1AT) deficiency results from a genetic disorder at 2 common loci. Diagnosis requires quantification of A1AT and subsequent identification of the specific variant. The current algorithm of laboratory testing for the diagnosis of A1AT deficiency uses a combination of quantification (nephelometry), genotyping, and/or phenotyping. We developed a multiple reaction monitoring liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of A1AT and identification of the 2 most common deficiency alleles present in 95% of the patients with A1AT deficiency.METHODSSerum samples (n = 40) were digested with trypsin, and appropriate 13C/15N-labeled standard peptides were added. We performed LC-MS/MS analysis with a 0.5- by 150-mm C18 column and H2O:acetonitrile:n-propanol:formic acid (A:98:1:1:0.2 and B:10:80:10:0.2; flow 12 μL/min) mobile phase in positive ion mode on a TSQ Quantum triple quadrupole MS system. We measured the A1AT concentration by comparison to a calibration curve and determined the phenotype by the presence or absence of variant peptides. We compared the results to the current phenotyping assay by isoelectric focusing (IEF) and the immunonephelometry quantitative assay.RESULTSFor A1AT allele detection, in 39 of 40 samples the LC-MS/MS results were identical to those obtained by IEF gel electrophoresis. The single discrepant result was rerun by IEF at a lower dilution, and the results were in concordance. The A1AT quantification by LC-MS/MS also compared favorably with nephelometry.CONCLUSIONSThe LC-MS/MS method correlates well with current phenotyping and nephelometric assays and has the potential to improve the laboratory diagnosis of genetic A1AT deficiency.
A new transthyretin variant Leu55Gln in a patient with systemic amyloidosis
Yazaki, Masahide , Varga, John , Dyck, P. James B. , Benson, Merrill D.

Mayo Clinic

Amyloid | March 1, 2011 | Volume: 9 | Issue: 4 | Pages: 268-271

10.3109/13506120209114105 | PMID 12557757 Get It

Determination of Aspartame and Caffeine in Carbonated Beverages Utilizing Electrospray Ionization-Mass Spectrometry
Bergen, H. Robert, Benson, Linda M., Naylor, Stephen

Mayo Clinic

Journal of Chemical Education | December 17, 2009 | Volume: 77 | Issue: 10 | Pages: 1325

10.1021/ed077p1325 Get It

Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set
Gramont, Aimery de , Shi, Qian , Benedetti, Jacqueline, Bot, Brian M. , O’Callaghan, Chris J. , Yothers, Greg , Goldberg, Richard M. , Blanke, Charles D. , Benson, Al B. , Deng, Qiqi , André, Thierry , Sargent, Daniel J. , Hubbard, Joleen M. , O’Connell, Michael J. , Buyse, Marc , Alberts, Steven R. , Wolmark, Norman , Grothey, Axel , Sargent, Daniel J , André, Thierry , Shi, Qian , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | December 15, 2009 | Volume: 28 | Issue: 3 | Pages: 460-465

10.1200/jco.2009.23.1407 | PMID 20008641 Get It

Purpose We previously validated disease-free survival (DFS) as a surrogate for overall survival (OS) in fluorouracil-based adjuvant colon cancer clinical trials. New therapies have extended survival after recurrence from 1 to approximately 2 years. We examined the possible impact of this improvement on the DFS/OS association. Methods The Adjuvant Colon Cancer Endpoints (ACCENT) data set of 20,898 patients was analyzed. In an exploratory fashion, time from recurrence to death in patients experiencing recurrence was extended using several algorithms, and the association of DFS after 3 years of median follow-up and OS after varying lengths of follow-up (median of 5, 6, and 7 years) was assessed. Results Seven thousand four hundred two patients (35%) experienced recurrence. Median time from recurrence to death was 24 months in the hypothetical data sets. When times from recurrence to death were doubled, the association between treatment effects on DFS and 5-year OS was modest (R2 = 0.51 for both 2- and 3-year DFS) but remained strong for DFS and 6-year OS (R2 = 0.67 for both 2- and 3-year DFS) and 7-year OS (R2 = 0.70 for both 2- and 3-year DFS). The reduced DFS/OS association with extended survival after recurrence was greater in stage II than stage III patients. Multiple simulations provided consistent findings. Conclusion Extended survival after recurrence reduces the association between treatment effects on 3-year DFS and 5-year OS, particularly in stage II patients; longer follow-up strengthens the association. In modern adjuvant trials, 6 or 7 years may be required to demonstrate OS improvements, further supporting DFS as the preferred primary end point for future adjuvant colon cancer clinical trials.
Recognition of Fungal Protease Activities Induces Cellular Activation and Eosinophil-Derived Neurotoxin Release in Human Eosinophils
Matsuwaki, Yoshinori , Wada, Kota, White, Thomas A. , Benson, Linda M., Charlesworth, M. Cristine , Checkel, James L., Inoue, Yoshinari, Hotta, Kyôko, Ponikau, Jens U., Lawrence, Christopher B. , Kita, Hirohito , Charlesworth, M. Cristine , Hotta, Kyoko, Kita, H

Mayo Clinic

The Journal of Immunology | October 29, 2009 | Volume: 183 | Issue: 10 | Pages: 6708-6716

10.4049/jimmunol.0901220 | PMID 19864598 Get It

Abstract Eosinophils are multifunctional leukocytes implicated in the pathogenesis of asthma and in immunity to certain organisms. Associations between exposure to an environmental fungus, such as Alternaria, and asthma have been recognized clinically. Protease-activated receptors (PARs) are G protein-coupled receptors that are cleaved and activated by serine proteases, but their roles in innate immunity remain unknown. We previously found that human eosinophils respond vigorously to Alternaria organisms and to the secretory product(s) of Alternaria with eosinophils releasing their proinflammatory mediators. In this study, we investigated the roles of protease(s) produced by Alternaria and of PARs expressed on eosinophils in their immune responses against fungal organisms. We found that Alternaria alternata produces aspartate protease(s) and that human peripheral blood eosinophils degranulate in response to the cell-free extract of A. alternata. Eosinophils showed an increased intracellular calcium concentration in response to Alternaria that was desensitized by peptide and protease ligands for PAR-2 and inhibited by a PAR-2 antagonistic peptide. Alternaria-derived aspartate protease(s) cleaved PAR-2 to expose neo-ligands; these neo-ligands activated eosinophil degranulation in the absence of proteases. Finally, treatment of Alternaria extract with aspartate protease inhibitors, which are conventionally used for HIV-1 and other microbes, attenuated the eosinophils’ responses to Alternaria. Thus, fungal aspartate protease and eosinophil PAR-2 appear critical for the eosinophils’ innate immune response to certain fungi, suggesting a novel mechanism for pathologic inflammation in asthma and for host-pathogen interaction.